Phase II study of mitolactol in chemotherapy-refractory metastatic breast cancer.
Thirty-eight evaluable patients with metastatic breast cancer refractory to hormonal therapy and multiple chemotherapy regimens were treated with mitolactol at a dose of 130 mg/m2/day orally for 10 days every 6 weeks. Only one patient, with nodal and chest wall metastases, had a sustained complete regression; two patients had stable disease; and 35 patients had disease progression. The toxicity, which was primarily hematologic, was acceptable.
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy*; D003520:Cyclophosphamide / Q000008:administration & dosage; D004341:Drug Evaluation; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D008936:Mitolactol / Q000627:therapeutic use* / Q000633:toxicity; D009362:Neoplasm Metastasis; D011960:Receptors, Estrogen / Q000032:analysis
D000970:Antineoplastic Agents; D011960:Receptors, Estrogen; D003520:Cyclophosphamide; D008936:Mitolactol; D005472:Fluorouracil; D008727:Methotrexate